Centre François Baclesse

Running trials

• Not yet recruiting

  Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

  NCT06726330· Centre Oscar Lambret· Source

• Not yet recruiting

  Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial

  NCT07915037· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC

  2026-526300-67-00· Phase 3· Summit Therapeutics Inc.· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.

  NCT07733817· Centre Francois Baclesse· Source

• Not yet recruiting

  Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

  NCT07717450· Phase 3· UNICANCER· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Daiichi Sankyo· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· AstraZeneca· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· UNICANCER· Source

• Not yet recruiting

  Reduction of treatment after Complete Response in Advanced Hormone-Sensitive Breast Cancer

  2026-526319-12-00· Phase 3· Unicancer· Source

• Not yet recruiting

  SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer

  NCT07241273· UNICANCER· Source

• Not yet recruiting

  Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

  NCT07359456· Phase 2· UNICANCER· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Not yet recruiting

  Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

  NCT07637851· Phase 1/2· ARCAGY/ GINECO GROUP· Source

• Recruiting

  Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test

  2025-521045-24-00· Phase 3· Unicancer· Source

• Recruiting

  Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma who progressed within 6 months of multimodality therapy for locally advanced disease.

  2025-521437-88-00· Phase 2· Groupe Oncologie Radiotherapie Tete Cou· Source

• Not yet recruiting

  Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

  NCT07437287· Phase 2/3· UNICANCER· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

  NCT07264075· Phase 3· Groupe Oncologie Radiotherapie Tete et Cou· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Radiopharmaceutical Treatment of Advanced Kidney Cancer

  NCT06783348· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Recruiting

  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  NCT07431827· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab)

  2023-506291-28-00· Phase 3· Centre Leon Berard· Source

• Recruiting

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  2025-522151-26-00· Phase 3· Arrivent Biopharma Inc.· Source

• Recruiting

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· Phase 3· AstraZeneca· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

  NCT07451002· Janssen Cilag S.A.S.· Source

• Recruiting

  To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participants with Breast Cancer

  2025-521128-31-00· Phase 1/2· Genentech Inc.· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

  NCT06908993· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.

  2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source

• Recruiting

  Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  2025-520555-89-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· Phase 2· AbbVie· Source

• Recruiting

  Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

  NCT06656598· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients

  NCT06846346· Phase 2· Unicancer· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

  NCT06599879· Institut Claudius Regaud· Source

• Recruiting

  Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

  NCT06529718· Phase 2· UNICANCER· Source

• Recruiting

  Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

  NCT07205731· Phase 2· University Hospital, Clermont-Ferrand· Source

• Active, not recruiting

  Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)

  2025-521681-10-00· Phase 2· Revolution Medicines Inc.· Source

• Recruiting

  Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

  NCT07028125· Phase 4· Centre Francois Baclesse· Source

• Recruiting

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  NCT07022483· Phase 3· Daiichi Sankyo· Source

Showing 50 of 253.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer41 recruiting
• Metastatic breast cancer22 recruiting
• Colorectal cancer18 recruiting
• Ovarian cancer15 recruiting
• Prostate cancer13 recruiting
• Head and neck cancer11 recruiting
• Endometrial cancer10 recruiting
• Childhood cancers9 recruiting
• Gastric and oesophageal cancer8 recruiting
• Kidney cancer8 recruiting
• Neuroendocrine tumours7 recruiting
• Triple-negative breast cancer7 recruiting
• Sarcoma6 recruiting
• Bladder cancer5 recruiting
• Liver and biliary tract cancer5 recruiting
• Pancreatic cancer3 recruiting
• Cervical cancer2 recruiting
• Glioblastoma2 recruiting
• Melanoma2 recruiting
• Meningioma2 recruiting
• Neuroblastoma1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Completed

  Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE

  NCT06535997· Hospices Civils de Lyon· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

  NCT06735781· Bristol-Myers Squibb· Source

• Active, not recruiting

  Volrustomig Priming Regimens Exploratory Phase II Platform Study

  NCT06448754· Phase 2· AstraZeneca· Source

• Completed

  Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

  NCT06599463· ARCAGY/ GINECO GROUP· Source

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· UNICANCER· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Ipsen Innovation· Source

• Active, not recruiting

  Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2023-503428-24-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma.

  NCT04718675· Phase 1· Kronos Bio Inc.· Source

• Completed

  Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patients with head and neck cancer.

  2022-502584-38-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source

• Completed

  Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

  NCT06660147· ARCAGY/ GINECO GROUP· Source

• Completed

  Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic Carninoma of the Head and Neck

  2023-503270-20-00· Phase 1· Groupe Oncologie Radiotherapie Tete Cou· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

  NCT06003231· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.

  2022-502372-22-01· Phase 2· Unicancer· Source

• Terminated

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· Phase 2· UNICANCER· Source

• Recruiting

  A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors

  NCT05642780· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.· Source

• Terminated

  Study of ART0380 in Patients With Biologically Selected Solid Tumors

  NCT05798611· Phase 2· Artios Pharma Ltd· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source

• Completed

  Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

  NCT03744468· Phase 1/2· Beigene Ltd.· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  2023-505816-39-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Active, not recruiting

  ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

  NCT05650879· Phase 1· Enliven Therapeutics· Source

• Completed

  First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients

  2022-501183-17-00· Phase 1/2· Inhatarget Therapeutics· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Merck Healthcare KGaA· Source

• Active, not recruiting

  Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

  NCT05609578· Phase 2· Mirati Therapeutics Inc.· Source

• Completed

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· Phase 3· Arcus Biosciences, Inc.· Source

• Completed

  A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer

  NCT05328908· Phase 3· Bristol Myers Squibb International Corporation· Source

• Recruiting

  Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

  NCT05254171· Phase 2/3· Panbela Therapeutics, Inc.· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Completed

  Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.

  NCT05303129· Centre Francois Baclesse· Source

• Active, not recruiting

  A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

  NCT05307705· Phase 1· Eli Lilly and Company· Source

• Completed

  Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)

  2024-512826-26-00· Phase 2· Institut Gustave Roussy· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT05089734· Phase 3· Gilead Sciences· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

  NCT04736485· Phase 2· Centre Francois Baclesse· Source

• Completed

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· Phase 3· G1 Therapeutics, Inc.· Source

• Completed

  Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC

  NCT04725396· UNICANCER· Source

• Completed

  A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

  NCT04665843· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· Phase 3· Mirati Therapeutics Inc.· Source

• Completed

  Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

  NCT04704219· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

  NCT04547504· Phase 3· University Hospital, Brest· Source

• Completed

  The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

  NCT04338399· Phase 3· Adlai Nortye Biopharma Co., Ltd.· Source

• Terminated

  Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

  NCT04450836· Phase 2· UNICANCER· Source

• Completed

  Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy

  NCT04481893· Centre Francois Baclesse· Source

• Completed

  Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

  NCT04357873· Phase 2· UNICANCER· Source

• Completed

  A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Patients with Advanced Solid Tumors and Subsequent Expansion Cohorts

  2024-518506-41-00· Phase 1/2· Promontory Therapeutics Inc.· Source

• Completed

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

Showing 50 of 99.

Conditions

Diseases this institution publishes on or runs trials for.

• Ovarian cancer28 works · 37 trials
• Metastatic breast cancer24 works · 56 trials